Search Results

Bio NC

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2024

Chimerix announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix’s common stock.

April 16, 2024

·

1 min read

Press Releases

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

March 5, 2025

·

14 min read

Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.

Mergers & acquisitions

Jazz Expands Cancer Expertise With $935M Chimerix Buy

At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 K27M-mutated diffuse glioma.

March 5, 2025

·

2 min read

·

Tristan Manalac

Press Releases

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

March 21, 2025

·

7 min read

Bio NC

Chimerix to Participate in Fireside Chat at Jefferies 2024 Global Healthcare Conference

Chimerix announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.

May 30, 2024

·

1 min read

Business

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

Chimerix reported financial results for the first quarter ended March 31, 2024 and provided an operational update.

May 1, 2024

·

9 min read

Business

Chimerix Appoints Marc D. Kozin to Board of Directors

Chimerix, a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors.

March 21, 2024

·

2 min read

Deals

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock.

November 24, 2023

·

1 min read

Axial view of the brain showing a glioblastoma in the left frontal lobe with central necrosis, peripheral infiltration, and early midline shift.

Brain cancer

FDA Greenlights Jazz’s Dordaviprone, First New Treatment for Ultra-Rare Brain Tumor

The small molecule drug, acquired by Jazz Pharmaceuticals in its $935 million Chimerix pick-up this spring, is intended for relapsed adult and pediatric patients with H3 K27M mutations.

August 6, 2025

·

2 min read

·

Dan Samorodnitsky

Press Releases

Chimerix to Speak Today at The White House Cancer Moonshot Forum

January 14, 2025

·

3 min read